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Dear Editor, 
With this letter we would like to describe the most recent evidences highlighting the crucial role of 
autoimmunity in Amyotrophic Lateral Sclerosis (ALS) pathogenesis. 
ALS is a neurodegenerative disorder characterised by a progressive death of motor neurons, 
resulting in fatal paralysis in a few years. Hereditary ALS, account for 10% of the cases while in the 
remaining non-hereditary 90% ALS and does not show any conventional hereditary pattern [1]. The 
only established risk factors to date are older age, male gender, and a family history of ALS [1]. 
The cause of ALS and the specific mechanisms of neuronal death remain unknown. Considerable 
evidences support the existence of autoimmune mechanisms contributing to pathogenesis in ALS, 
including biochemical, morphological, pharmacological, and physiological studies [1]. Typical 
hallmarks of autoimmunity, such as circulating immune complexes, higher frequency of a particular 
histocompatibility type, or association with other autoimmune diseases, have also been reported [2]. 
An important marker of autoimmunity is the degree of T-lymphocytic infiltration in the anterior 
horn of the spinal cord of ALS patients [3]. Hence, inflammation in the ALS spinal cord and brain 
appears to be primarily due to T-cells and macrophages [4], and aberrant macrophage activity is 
believed by many investigators to contribute to the pathology underlying ALS. 
This may explain the recent promising results of an ALS phase 2 clinical trial of NP001, a regulator 
of inflammatory macrophage activity [5]. Although the predefined endpoints in this study did not 
reach statistical significance, administration of NP001 was associated with cessation in disease 
progression in 27% of patients, approximately 2.5 times greater than the percentage in patients on a 
placebo. Two major plasma markers of inflammation, IL-18 and lipopolysaccharide, differentiated 
NP001 responders from non-responders, suggesting that the subgroup of patients with greater 
baseline biomarkers of neuroinflammation experienced the most benefit [5].  
Additional evidence pointing toward pathologic involvement of autoimmune processes is the 
finding that immunoglobulins from ALS patients have been shown to cause apoptosis of motor 
neurons in primary spinal cord cultures and that passive transfer of immunoglobulins to mice 
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caused degeneration of motor neurons [6]. These findings suggest that antibodies can contribute to 
disease pathogenesis. Increased levels of interleukins IL-17 and IL-23 have also been found in 
serum and cerebrospinal fluid of ALS patients. This increment is thought to be a sign of T-helper 17 
activation, a subset of T-cells suggested to be crucial in destructive autoimmunity.  
Additional support for the autoimmune pathogenesis hypothesis is the finding that ALS has recently 
been included in the spectrum of neurologic manifestations associated with voltage-gated potassium 
channel (VGKC) autoimmunity [7].  
Ample evidence now points to a contribution of the innate immune system in ALS. In line with this, 
microglial cell activation can be found at the sites of neurodegeneration. In addition, the importance 
of microglia in ALS has recently been highlighted by a study demonstrating that classical NF-κB 
activation is required to induce motor neuron death in a mutant superoxide dismutase 1 (SOD1G93A) 
mouse model of ALS. These findings are further substantiated by PET imaging of patients with 
ALS, and studies have suggested that microglial cell activation is increased in affected brain areas. 
In addition, the extent of microglial cell activation positively correlated with the severity of clinical 
symptoms in these studies [8].  
The innate immune system may affect the function and survival of motor neurons in ALS by at least 
three mechanisms. First, there is evidence to suggest that aggregates of mutant SOD1—which is 
derived from microglial and astroglial cells—activate neighbouring microglia by binding to TLR2, 
TLR4, and CD14, and subsequently promote neuronal cell death [9]. Second, the release of pro-
inflammatory cytokines may drive motor neuron damage. Third, although poorly understood, a 
mechanism has been suggested on the basis of the functional analysis of microglial cells that 
express mutant SOD1 [10]. These cells showed impaired overall motility and a reduced capacity to 
clear neuronal cell debris. Impairment of microglial cell phagocytosis may therefore contribute to 
the accumulation of further immunostimulatory proteins, including mutant SOD1, chromogranin A, 
and dsRNA, thereby resulting in disease progression.  
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